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Abstract
Using HCV and IFN-resistance as a proof of concept, we have devised a new methodology for 
calculating the effect of a drug over a viral population and the resistance of its individual intra-
host variants.
By means of next-generation sequencing, HCV variants were obtained from sera collected at 9 
time-points from 16 patients during the first 48 hours after injection of IFN-α. IFN-resistance 
coefficients were calculated for individual variants using changes in their relative frequencies, and 
for the entire intra-host viral population using changes in viral titer during the initial 48 hours.
Population-wide resistance and presence of IFN-resistant variants were highly associated with 
pegIFN-α2a/RBV treatment outcome at week 12 (p = 3.78×10-5 and 0.0114, respectively). This 
new method allows an accurate measurement of resistance based solely on changes in viral titer or 
the relative frequency of intra-host viral variants during a short observation time.
There has been a great progress in the development of antiviral agents licensed for treatment 
of Human immunodeficiency virus (HIV), Herpesviruses, Hepatitis viruses and respiratory 
viruses1. The emergence of HIV as a major human pathogen and the intensive use of 
antiretroviral compounds have also provided a better understanding of the genesis of 
antiviral resistance2. However, there is not a simple method for measuring directly the effect 
a drug has over a viral population and its individual intra-host variants. Such measure could 
help screen promising drugs that affect the viral population and also detect the individual 
variants that are naturally more resistant. In this paper, we use the effects of Interferon (IFN) 
on HCV as a proof of concept, finding that our drug-resistance estimates, calculated during 
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the first 48 hour after IFN injection, are strongly associated with outcome of therapy at week 
12.
Hepatitis C virus (HCV) infects nearly 3% of the world's population and is a major cause of 
liver disease worldwide3. There is no vaccine against HCV and up to recently the standard-
of-care therapy involved the combined use of pegylated interferon (peg-IFN) and ribavirin 
(RBV). This combination therapy is expensive, effective in only 50%-60% of patients, and 
can be associated with frequent and serious adverse side effects in more than 75% of 
patients4, 5 In order to improve cost-effectiveness and ameliorate patient hardship, it would 
be desirable to predict the response at early onset of therapy.
IFNs are crucial components of the innate immune system. IFN-α acts by inducing 
production of interferon stimulating genes (ISGs) to establish a non-specific antiviral state 
within the cell with direct inhibition of viral replication. It is also known to exert 
immunomodulatory effects that enhance immune response and accelerate clearance of 
infected cells6. When exogenously administered as a single injection, IFN-α induces a 
decline of HCV RNA in two phases: a rapid phase lasting for 24-48 hours, followed by a 
slower phase of decline over the ensuing weeks. The initial rapid decline is defined by the 
rate of viral clearance and the effectiveness of IFN in blocking viral production. Successful 
treatment results in sustained undetectable HCV RNA after completion of therapy. 
Treatment failure results either from nonresponse (minimal declines in viral titer during 
therapy) or relapse (robust initial responses followed by rebounds of viral titers after 
therapy)6.
Several independent predictors of a sustained virologic response (SVR) to IFN/RBV therapy 
have been identified. These include HCV genotypes 2 and 3, low pretreatment viral load, 
Asian or Caucasian ethnicity, younger age, absence of advanced fibrosis or cirrhosis, and 
absence of steatosis7. More recently, Genome Wide Association Studies have identified 
single-nucleotide polymorphisms near the IL28B gene (encoding IFN-λ3) as being 
particularly associated with spontaneous and treatment-induced clearance of HCV 
infection8, 9. However, IL28B variations may account for only ∼15% of inter-individual 
variability of SVR10. The interaction of these host factors determines the therapy effect on 
the virus, which is directly evidenced by a decline in viral titer, the reason why the rate and 
magnitude of decline in the first weeks of treatment can predict the outcome of therapy6.
HCV exists in infected patients as a large viral population of intra-host variants, which may 
be differentially resistant to IFN treatment and, therefore, likely to display variable temporal 
patterns during the first phase of decline following IFN injection. Assessing the spectrum of 
HCV variants and measuring the IFN resistance of individual variants could be critical for 
understanding the variability in therapy outcomes. Next-generation sequencing (NGS) 
technologies in conjunction with computational analysis allow for quantitative assessment of 
viral intra-host variants, providing data on the intra-host dynamics of individual HCV 
variants and an opportunity for measuring their resistance to IFN. The HVR1 region of HCV 
is used here as a tag or marker of individual intra-host viral strains for estimating their 
relative frequencies over a short period of time.
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Since the model is based solely on changes in viral titer or the relative frequency of intra-
host viral variants persisting during antiviral therapy, without consideration of other viral 
factors, host factors or type of drug administered, it may be applicable to measure and 
predict HCV treatment response with other drug regimens, including the newly available 
direct acting antiviral (DAA) agents. In addition, the presented analytical framework should 
be applicable to drug resistance of other viral infections.
Results
Outcomes of therapy
The demographics and clinical features of the 16 study patients are summarized in Table 1, 
which includes their gender, race, grade of hepatic inflammation and fibrosis, IL28 genotype 
(see also figure 2A) and therapy outcome according to the clinical criterion of treatment 
success11, 12: (i) Rapid Virological Response (RVR) is defined as having undetectable HCV 
RNA by week 4 of therapy (n=4); (ii) Early Virological Response (cEVR): undetectable 
HCV RNA by week 12 of therapy (n=6); (iii) partial Early Virological Response (pEVR): a 
decrease of HCV RNA more than 2 log10 but still detectable after 12 weeks of therapy 
(n=4); and (iv) non-response (NR): decrease of HCV RNA less than 2 log10 after 12 weeks 
of therapy (n=2). The inefficiency of IL28B as the sole predictor of IFN-based therapeutic 
response is highlighted in Figure 2A, which displays the number of patients by IL28B status 
and therapy outcome.
Decline of viral titer during the first 48 hours after single-dose injection
HCV RNA level was measured at each time-point (Figure 1) and interpolated over the entire 
48 hours. The titer declined in all patients, starting from an average of 4.76 hours after IFN 
injection (standard deviation [SD] 2.23 hours), with the lowest point being observed at 30.03 
hours (S.D. 4.66 hours), and an average drop of 1.67 log10 IU/ml. The HCV RNA titer rised 
at 48 hours in all patients with an average increase of 0.86 log10 IU/ml compared to the 
lowest titer, which likely corresponded to the gradual clearance of the administered IFN 
(Figure 1). All calculations conducted in this paper used all time-points, but we found four 
time-points (0, 24, 36 and 48 hours) which are particularly critical for the calculation of 
resistance. This is due to the fact that the most important changes in viral titer occur around 
these time-points.
Association of the population IFN-resistance with outcome of treatment at week 12
The population IFN-resistance coefficient was calculated using the rate of titer change as 
described in Equation 3. A positive coefficient value indicates IFN-resistance, whereas a 
negative value indicates IFN-sensitivity. Figure 2B shows the association of the coefficient 
values with therapy outcomes. The lowest coefficient value was calculated for RVR 
followed by cEVR and pEVR, with the highest value calculated for NR. The average 
population IFN-resistance coefficients for the four outcomes were significantly different (p-
value = 3.78×10-5), being 3.03 times higher for non-responders (pEVR and NR) than for 
responders (RVR and cEVR) (p-value = 0.0040) (Figure 2B). Thus, the resistance 
coefficients calculated using data from the first 48 hours strongly correlated with therapy 
outcome at week 12.
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Stability of intra-host HCV subpopulations
Given the strong association between population IFN-resistance coefficient values and 
therapy outcome, we investigated whether this association could be attributed to resistance 
of individual HCV variants. The HCV E1/E2 region from all samples was subjected to deep-
sequencing, generating a total of 1,763,502 reads, with an average of 12,332 reads per time-
point (Figure 2D). Many low-frequency intra-host viral variants could not be detected at all 
time-points, with numerous variants detectable only at a single time-point. However, the 
spectrum of frequent intra-host HCV variants was stable. On average, 76.81% (SD 17.66%) 
of all error-corrected reads found at 48 hours were also present before therapy. The less 
persistent variants were usually found at very low frequencies, suggesting that their absence 
at some time-points is likely due to stochastic sampling. The nucleotide diversity of each 
time-point was calculated and also found to be constant in all patients, with the SD of the 
nucleotide diversity ranging from 0.0001 in Patient 2 to 0.0139 in Patient 14.
Phylogenetic analysis showed that major viral subpopulations were constantly present 
during the entire sampling period in all patients. However, many low-frequency variants 
could be detectable at only certain time-points. Genetic differences between time-points 
were measured for each patient using Φst. Viral populations found at the first and last time-
points were very similar in most patients, the average Φst being only 3.52%, with only one 
patient (Patient 6) showing a high Φst value (71.14%) (see Table 2).
Association between presence of IFN-resistant variants and therapy outcome
Sequences of intra-host HCV variants were not expected to accrue mutations over 48 hours 
of observation. However, we found that the relative frequencies of persistent variants 
changed during the time period in all patients (Figure 3). The developed mathematical 
model allowed calculation of the IFN resistance coefficient for each persisting intra-host 
HVR1 variant based on its relative frequency variations. IFN-resistance varied broadly 
among intra-host variants in all patients.
Not a single IFN-resistant variant was found in patients with RVR and only one of six cEVR 
patients showed IFN-resistant variants (Table 2 and Figure 4A). In contrast, patients with 
pEVR and NR were infected with an average number of 3.25 and 3.5 IFN-resistant intra-
host variants, respectively (Figure 4A). The average number of IFN-resistant variants was 
significantly associated with the four outcomes (p = 0.0114), being 16.6 times lower for 
non-responders (pEVR and NR) than for responders (RVR and cEVR) (p = 0.0014). The 
average total fraction of reads with positive IFN-resistance values was also significantly 
different among the four outcomes (p = 0.0014) (Figure 4C). These observations suggest 
that the absence or presence of IFN-resistant variants and their frequency prior to single-
dose IFN injection are strong predictors of treatment outcome.
In all patients, the variant with the highest initial frequency (henceforth referred to as the 
major variant) showed a strong sensitivity to IFN, with an average value of -4.75 over all 
patients (Table 2). The average IFN-resistance of the major variants for the four outcomes 
was significantly different (p = 0.0071), being 3.68 times higher for non-responders (pEVR 
and NR) than for responders (RVR and cEVR) (p = 0.0028) (Figure 4B). There was no 
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association between the therapy outcome and the initial frequency of the IFN-sensitive 
major variant (p = 0.1535). The maximum IFN-resistance found in each patient was 
significantly different among the four outcomes (p = 0.0188), being 5.25 times higher for 
non-responders (pEVR and NR) than for responders (RVR and cEVR) (p = 0.0084) (Figure 
4D).
Phylogenetic analysis of sensitive and resistant variants
For all patients showing one or more IFN-resistant variants, we performed a phylogenetic 
analysis to ascertain the genetic relatedness between the sensitive and resistant variants. For 
each patient, resistant variants were always one or two nucleotides different from the 
sensitive variants in the same cluster. In addition, resistant sequences did not cluster together 
but were scattered mostly across other subpopulations (Figure 5).
Discussion
Viral kinetic modeling has played an important role in analysis of HCV decay in peripheral 
blood (as measured by serum or plasma HCV RNA) after initiation of antiviral therapy13-15. 
Kinetic models usually include such parameters as viral load, number of target cells, number 
of infected cells producing virions, target cell production rate, target cell death rate, de novo 
infection rate constant, infected cells death rate, HCV virion production rate and HCV virion 
clearance rate. A recent study15 of 2100 patients from two clinical trials further developed a 
kinetic analysis based on a model that incorporates variables such as liver regeneration, 
HCV RNA below threshold of detection and a cure boundary. Although useful for 
understanding HCV pathogenesis and replication, such models require substantial a priori 
knowledge and assumptions, and data collected over 24 to 72 weeks of therapy.
It is the interaction of several host factors that determines the therapy effect on the virus, but 
such effect is directly evidenced by a decline in viral titer, the reason why the rate and 
magnitude of decline in the first weeks of treatment can predict the outcome of therapy6. 
The decline in viral titer observed among the patients during the first 48 hours after a single 
IFN injection indicates that their intra-host viral populations were under considerable 
selective pressure after the medication. Although the spectrum of intra-host HCV variants 
was relatively stable over that time period, we found that the frequencies of the persistent 
HCV variants were variable. This allowed the degree of IFN-resistance to be calculated for 
the individual intra-host HCV variants. We took advantage of the capacity of NGS to 
produce a massive number of sequences, facilitating accurate and robust assessment of the 
frequency of viral variants.
All calculations conducted here used 9 time-points, but the collection and sequencing of 
serum samples at such frequency is difficult for routine research or eventual patient 
evaluation. However, we found four time-points, 0, 24, 36 and 48 hours, to be sufficient for 
the calculation of resistance. Viral titer at these time-points reflects most closely the effect of 
IFN on viral population. It should be noted that the specific time-points, which are most 
critical for estimation of resistance coefficients, may differ for other drugs from those found 
in this study, owing to differences in mechanisms of action and clearance kinetics of drugs.
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HVR1 is used here as a tag or marker of individual intra-host viral strains for estimating the 
relative frequency of intra-host HCV genomic variants. However, this relatively short region 
may be shared by more than one genetically distinct genomic variant. Nonetheless, HVR1 is 
the most heterogeneous region of the viral genome, so the probability of such sharing is 
minimized. Furthermore, we previously demonstrated that coordinated evolution among 
sites from the entire HCV genome is strongly associated with IFN resistance, and that 
sequence polymorphisms in short genomic regions, including HVR1, can accurately reflect 
that association16.
Phylogenetic analysis showed that IFN-resistant variants were one or two nucleotides 
different from sensitive variants, but both resistant and sensitive variants belonged to the 
same cluster, rather than being segregated. The association between variation in the HVR1 
sequence and therapy outcome is therefore unlikely to be mediated by the few mutations in 
HVR1, but rather by other regions of the HCV genome, with HVR1 heterogeneity reflecting 
genetic variation in these regions, as we have previously shown16, 17.
Patient 16 was the only one from the group of responders (four RVR and six cEVR patients) 
who carried IFN-resistant variants with a value similar to that of pEVR and NR patients. 
The reasons for this discrepancy between outcome and our estimates are difficult to 
ascertain, although it was observed that this patient lost 62.5% of its titer within 2 days 
before IFN treatment. The results raise the interesting possibility that this patient cleared the 
HCV infection independently of the IFN treatment.
This study is the first to apply a mathematical model using empirically derived viral kinetic 
data with viral sequences linked to the frequency of their persistence. We found that 
frequency changes of the viral population associate strongly with treatment outcome. Since 
the model is based solely on changes in viral titer or the relative frequency of intra-host viral 
variants persisting during antiviral therapy, without consideration of other viral factors, host 
factors or type of drug administered, it is applicable to measure and predict HCV treatment 
response with other drug regimens, including the newly available direct acting antiviral 
(DAA) agents. The analytical framework developed here should be applicable as well to the 
drug response of other viral infections, as long as informative samples are collected at time-
points reflecting variation in viral titer associated with the action of specific drugs on the 
virus under investigation.
Methods
Patients
Sixteen treatment-naïve patients with genotype 1 chronic hepatitis C were studied. Blood 
samples were collected from each patient over 48 hours (at time-points 0 (baseline), 1, 3, 6, 
12, 18, 24, 36 and 48 hours) after a single subcutaneous injection of IFN-α (10 MU). 
Patients then received a course of pegylated IFN-α2a and ribavirin starting 48 hours after 
the single dose of IFN-α. Therapy continued for up to 48 weeks as per standard-of-care 
recommendation (see Lau et al.18 for more details). Ethical review and informed consent 
were granted by the institutional review boards of Beth Israel Deaconess Medical Center and 
the Centers for Disease Control and Prevention.
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Nucleic acid extraction
Total nucleic acids from the specimens were extracted from serum using the Roche MagNA 
Pure LC instrument and the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche 
Diagnostics, Mannheim, Germany). RNA was precipitated and reverse-transcribed using 
both random and specific primers as previously described19. PCR quantification was 
conducted by the COBAS AmpliPrep/COBAS Taq-Man HCV Test (Roche Diagnostics, 
Mannheim, Germany), and the HCV genotype determined using the VERSANT HCV 
Genotype 2.0 Assay (LiPA) (Innogenetics NV, Gent, Belgium).
HVR1 cDNA amplification
The E1/E2 junction of the HCV genome (309 nt), which contains the HVR1 region, was 
amplified using our nested PCR protocol as previously described19. The amplicons 
generated during first-round PCR were used as templates for nested PCR using hybrid 
primers composed of primer adaptors, multiple identifiers and specific sequences 
complementary to the HCV genome. This strategy allowed for multiplexing and 
downstream pyrosequencing. Resulting amplicons were quantified using the Picogreen kit 
(Invitrogen, Carlsbad, CA). Integrity of each fragment was evaluated using Bioanalyzer 
2100 (Agilent, Santa Clara, CA).
NGS
PCR products were pooled and subjected to pyrosequencing using the GS FLX System and 
the GS FLX Titanium Sequencing Kit (454 Life Sciences, Roche, Branford, CT). Low 
quality reads were removed using the GS Run Processor v2.3 (Roche). Initial reads were 
processed by matching to the corresponding identifier. The 454 files were processed using 
the error correction algorithms KEC and ET20, which have been validated to be highly 
accurate in finding true haplotypes, removing false haplotypes and estimating the frequency 
of true haplotypes. The error-corrected files were aligned using Muscle21 and the HVR1 
sequences clipped to 293 bp.
Genetic structure analysis
Unbiased estimates of nucleotide diversity were calculated according to Nei22 using 
ARLEQUIN23. We also measured the genetic differences between the first time-point (0 
hour) and the last time-point (48 hours) according to Excoffier et al.24 by means of 
ARLEQUIN23. The genetic structure was analyzed with consideration of the molecular 
differences between sequences in addition to differences in their frequencies, resulting in 
estimates of Φst, a measure of the percentage of genetic heterogeneity due to differences 
between two samples. Significance of the differences was estimated by use of a permutation 
test (n = 10,000). A maximum likelihood tree was built for the persistent variants of each 
patient by means of the software HyPhy25, using the General Time Reversible model. A 
Median-Joining network (MJN) was also built for each patient using the program 
NETWORK 4.626. The MJN method begins computing the minimum spanning trees (a 
graph that connects all sequences with the minimum total length of the branches), and then 
all these graphs are combined within a single (reticulate) network26.
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Nucleotide sequence accession numbers
The E1/E2 sequences produced in this study have been deposited in the National Center for 
Biotechnology Information GenBank database under accession numbers KC562310 to 
KC562900.
IFN-resistance coefficients
The dataset under consideration is HCV titer and sets of E1/E2 sequences with their relative 
frequencies for each time-point. In order to obtain reliable results in the calculation of IFN 
resistance for individual variants, only sequences present at every time-point were analyzed. 
The average fraction of persistent variants for all patients was 61.4% (ranging from 10.9% 
for Patient 6 to 94.9% for Patient 8).
The dynamics of the viral population consisting of n variants was described by the following 
system of differential equations27:
(1)
Here ui(t) and gi(t) are the frequency and the fitness of a variant i at time t, respectively; h(t) 
is the titer, ui(t), i=1,…, n and h(t) were interpolated on the whole segment from 0 to 48 
hours using cubic splines, and the derivatives u̇i(t) and ḣ(t) were calculated using the 
obtained spline approximations.
The average fitness during the studied time interval was used as a measure of the IFN-
resistance of each variant. Using the expressions for gi(t) obtained from (1), the individual 
variant IFN-resistance coefficient ri for each variant, i, was calculated by the following 
formula:
(2)
Here T = 48 hrs and t0 is the time when interferon begins affecting the viral population, 
which is estimated as the point when titer starts declining monotonically in the obtained 
spline approximation. The population IFN-resistance coefficient was calculated by the 
formula
(3)
To evaluate the estimates' quality of individual variants resistance, it was assumed that the 
correctly estimated fitnesses, ui(t), changed smoothly at the interval [0, 48]. Abrupt changes 
of ui(t) may indicate errors in the variant frequencies estimation due to PCR bias, 
sequencing inaccuracies, or both. The total variation of fitness on the interval [0,T] for each 
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variant was used as a measure of the possible error and was calculated using the following 
formula:
(4)
The variants with a variation greater than mean fitness variation over the whole population 
plus 2 standard deviations were excluded from analysis.
The justification of the model and derivations of formulas have been described in detail by 
Skums et al.27 All calculations were made in MATLAB R2010b (The Math Works, Inc., 
Natick, MA).
Statistical analysis
We tested the differences in IFN-resistance among therapy outcomes by means of a Multi-
Response Permutation procedure (MRPP)28, 29. MRPP is a permutation version of the t-test, 
a non-parametric test for testing the hypothesis of no difference between two groups of 
paired samples. Permutation tests represent ideal situations in which exact probabilities 
associated with a test statistic may be derived, rather than approximated from common 
probability distributions, such as t, F and Chi square30. In the majority of studies, the 
population distribution is unknown and assuming a normal distribution is inappropriate for 
many biological datasets, which often are skewed, discontinuous and multi-modal. We used 
the MRPP implemented in BLOSSOM28, using exact probabilities (all possible 
permutations) and V parameter equal to 1.
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Study Highlights
• What is the current knowledge on the topic?
There has been a great progress in the development of antiviral agents. 
However, there is not a simple method for measuring directly the effect a drug 
has over a viral population and its individual intra-host variants.
• What question this study addressed?
Whether next-generation sequencing can be used to estimate the drug resistance 
of a viral population.
• What this study adds to our knowledge?
Population-wide resistance and presence of drug-resistant variants were highly 
associated with treatment outcome.
• How this might change clinical pharmacology and therapeutics?
Since the model is based solely on changes in viral titer or the relative frequency 
of intra-host viral variants persisting during antiviral therapy, without 
consideration of other viral factors, host factors or type of drug administered, it 
is potentially applicable to measure and predict the drug response of other viral 
infections.
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Figure 1. 
HCV RNA level across all time-points. Patients are grouped according to treatment 
outcomes.
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Figure 2. 
A) Number of patients by IL28B status and therapy outcome. B) Population IFN-resistance 
for each patient. Blue: RVR; red: cEVR; yellow: pEVR; and green: NR. C) Average 
population IFN-resistance of patients for each outcome, bars correspond to standard error of 
the mean. D) Number of reads obtained by NGS from each patient and each time-point.
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Figure 3. 
Relative frequencies of persistent variants over time in all patients.
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Figure 4. 
Average IFN-resistance calculated over the patients of each therapy outcome. A) Number of 
IFN-resistant variants. B) IFN-resistance coefficient of the major variant. C) Fraction of the 
total number of reads that are IFN-resistant. D) Maximum IFN-resistance found. Bars 
correspond to standard error of the mean.
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Figure 5. 
Maximum likelihood trees of all the sequences from patients with resistant variants. Red: 
IFN-resistant variants; blue: IFN-sensitive variants.
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